公开(公告)号：US12240894B2

公开(公告)日：2025-03-04

申请号：US18313792

申请日：2023-05-08

Applicant: Prothena Biosciences Limited

Inventor： Gene Kinney ,  Wagner Marcelo Zago ,  Carol Karp ,  Radhika Tripuraneni

IPC: C07K16/18 ,  A61B5/00 ,  A61B5/0205 ,  A61B5/029 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61B5/11

Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.

公开(公告)号：US12195525B2

公开(公告)日：2025-01-14

申请号：US17937109

申请日：2022-09-30

Applicant: Prothena Biosciences Limited

Inventor： Peter Seubert ,  Philip James Dolan, III ,  Yue Liu ,  Robin Barbour

IPC: C07K16/18 ,  A61P25/28

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20240209073A1

公开(公告)日：2024-06-27

申请号：US18422712

申请日：2024-01-25

Applicant: Prothena Biosciences Limited

Inventor： Tarlochan S. Nijjar ,  Robin Barbour ,  Philip James Dolan, III ,  Yue Liu ,  Svetlana Alexander ,  Mark E. Renz

IPC: C07K16/18 ,  A61K9/00 ,  A61K45/06 ,  C12N15/63

CPC classification number: C07K16/18 ,  C12N15/63 ,  A61K9/0019 ,  A61K45/06 ,  C07K2317/565

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20240018226A1

公开(公告)日：2024-01-18

申请号：US18456932

申请日：2023-08-28

Applicant: Prothena Biosciences Limited

Inventor： Philip James Dolan, III

IPC: C07K16/18 ,  A61P25/28

CPC classification number: C07K16/18 ,  A61P25/28 ,  C07K2317/565 ,  C07K2317/77 ,  A61K2039/505

Abstract: The invention provides methods of treating taupathies such as Alzheimer's disease with antibodies that bind to human tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20230340094A1

公开(公告)日：2023-10-26

申请号：US18305109

申请日：2023-04-21

Applicant: Prothena Biosciences Limited

Inventor： Peter Seubert ,  Philip James Dolan, III ,  Yue Liu ,  Robin Barbour

IPC: C07K16/18 ,  A61K47/68 ,  A61P25/28 ,  A61K39/00 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K47/6843 ,  A61K47/6803 ,  A61P25/28 ,  A61K39/0007 ,  G01N33/6896 ,  C07K2317/24 ,  C07K2317/92 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/34 ,  C07K2317/55 ,  G01N2333/47 ,  G01N2800/2821

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20230331831A1

公开(公告)日：2023-10-19

申请号：US18313792

申请日：2023-05-08

Applicant: Prothena Biosciences Limited

Inventor： Gene Kinney ,  Wagner Marcelo Zago ,  Carol Karp ,  Radhika Tripuraneni

IPC: C07K16/18 ,  A61B5/0205 ,  A61B5/00 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/18 ,  A61B5/0205 ,  A61B5/4839 ,  A61B5/4842 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61B5/029

Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.

公开(公告)号：US20230126858A1

公开(公告)日：2023-04-27

申请号：US17937109

申请日：2022-09-30

Applicant: Prothena Biosciences Limited

Inventor： Peter Seubert ,  Philip James Dolan, III ,  Yue Liu ,  Robin Barbour

IPC: C07K16/18 ,  A61P25/28

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20220372118A1

公开(公告)日：2022-11-24

申请号：US17089599

申请日：2020-11-04

Applicant: Prothena Biosciences Limited

Inventor： Robin Barbour ,  Philip James Dolan, III ,  Yue Liu

IPC: C07K16/18 ,  A61K47/68 ,  A61P25/28 ,  G01N33/68

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US11267877B2

公开(公告)日：2022-03-08

申请号：US16753307

申请日：2018-10-05

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Joshua Reginald Salmans ,  Svetlana Alexander ,  Robin Barbour ,  Jeffrey N. Higaki ,  Tarlochan S. Nijjar

IPC: C07K16/18 ,  A61K31/713 ,  A61K45/06 ,  A61K39/00

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.

公开(公告)号：US20210261652A1

公开(公告)日：2021-08-26

申请号：US17181997

申请日：2021-02-22

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Tarlochan S. Nijjar ,  Robin BARBOUR ,  Philip James DOLAN, III ,  Yue LIU ,  Svetlana ALEXANDER ,  Mark E. RENZ

IPC: C07K16/18 ,  C12N15/63

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.